Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT06742580
Recruiting Observational

The Relationship Between Idiopathic Acute Peripheral Facial Paralysis and Homocysteine Level in Adult Patients

NCT06742580 · tracked via the Priya Life Science Turkey tracker
Sponsor
Murat Akın
Phase
Observational
Started
2023-12-01
Last updated
2024-12-19

Condition(s) studied

Facial Paralysis, PeripheralBell Palsy

Study summary

In the etıology of Idıopathıc Acute Perıpheral Facıal Palsy, known as bell palsy, many causes have been descrıbed, such as specıfıc ımmune, ıchemıc, ınfectıous and heredıal factors. ın our study, we have observed the blood homocysteıne level that causes thrombotıc dısorders ın paralysıs patıents.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: \- Patients admitted with acute facial paralysis Exclusion Criteria: * Facial and ear trauma or tumor * İatrogenic * Cholesteatoma * Facial paralysis due to central nervous system diseases

Primary outcome measure(s)

  • Homosystein test results — up to 24 weeks
    The results have not been obtained from lab yet. So none results were measured .

Trial sites (3)

FacilityCityRegionStatus
Afyonkarahisar Health Sciences University Afyonkarahisar Turkey (Türkiye) Active Not Recruiting
Afyonkarahisar Health Sciences University Afyonkarahisar Turkey (Türkiye) Recruiting
Afyonkarahisar Health Sciences University Afyonkarahisar Turkey (Türkiye) Recruiting

Other trials for the same condition

Turkish Validation of the Synkinesis Assessment Questionnaire (SAQ) Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06742580 on ClinicalTrials.gov ↗ ← All trials in Turkey